Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of ...

German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...

The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Cornell researchers have developed a stable, multi-target vaccine offering long-lasting protection against COVID-19 and ...

It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...

The Patent Trial and Appeal Board agreed with Pfizer and its German partner that Moderna's patents were invalid based on "prior art" that disclosed the inventions before Moderna patented them. The ...